Today: 11 June 2026
Browse Category

NASDAQ:CPB 9 December 2025 - 10 December 2025

Campbell’s (CPB) Stock Hits 52‑Week Lows After Q1 2026 Earnings and Fitch Downgrade – Is the 5.5% Dividend Worth the Risk?

Campbell’s (CPB) Stock Hits 52‑Week Lows After Q1 2026 Earnings and Fitch Downgrade – Is the 5.5% Dividend Worth the Risk?

Campbell’s shares hit a new 52-week low of $28.13 on December 10, dropping further after a post-earnings slide. Fitch downgraded the company’s credit rating to BBB- with a Stable outlook, citing high leverage and weak trends. Q1 fiscal 2026 results showed sales down 3% and adjusted EPS down 13%, but both slightly beat analyst estimates. Margins fell as tariffs and inflation drove costs higher.
10 December 2025
···

Stock Market Today

  • Johnson Controls International (JCI) Valuation Review Amid Recent Share Decline
    June 11, 2026, 10:52 AM EDT. Johnson Controls International (NYSE:JCI) shares fell 5.7% recently, despite solid annual revenue of US$24.4 billion and net income of US$2 billion. The stock trades slightly above its fair value estimate of US$138.11, which factors in a 9.38% discount rate and modest revenue growth forecast of 5.56%. Analyst models reflect steadier revenue expansion and improved profit margins, yet caution remains due to potential operational disruptions from a new segment structure and execution risks related to cost-saving initiatives. Investors are urged to evaluate both risks and rewards amid the short-term price weakness and maintain a close watch on ongoing financial performance and strategic execution.

Latest articles

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

11 June 2026
TOVX soared 74.6% to $0.4252 after Theriva Biologics published Phase 1 VCN-01 data showing survival and biomarker signals in head-and-neck cancer, but the jump was not due to drug approval or revenue; investors face ongoing financing, dilution, and clinical-trial execution risks, with the company’s cash runway only into Q1 2027 and substantial doubt about its ability to continue as a going concern without new capital.
Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

11 June 2026
Trulieve began NYSE trading as TRLV this week after moving from OTC/CSE, authorized a buyback of up to $50 million or 8.5 million shares, and closed its first NYSE session at $11.50, down 0.43%, before trading near $11.78 early Thursday, as investors weigh whether the uplisting and buyback will boost demand amid ongoing federal cannabis policy uncertainty.
Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

11 June 2026
Propanc Biopharma shares soared as much as 392% after authorizing up to $5 million in stock buybacks—exceeding its prior $3.1 million equity value—even as it reported just $443,702 in cash and flagged going-concern risks, with investors now focused on whether its lead cancer drug PRP will advance to a planned Phase 1b trial this year.
Go toTop